2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1382A
    Rac1 Inhibitor W56 TFA
    		Inhibitor 99.92%
    Rac1 Inhibitor W56 TFA is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor W56 TFA inhibits Rac1 interaction with guanine nucleotide exchange factors TrioN, GEF-H1, and Tiam.
    Rac1 Inhibitor W56 TFA
  • HY-144962
    SOS1-IN-11
    		Inhibitor 98.22%
    SOS1-IN-11 is a potent SOS1 inhibitor with an IC50 value of 30 nM.
    SOS1-IN-11
  • HY-12656
    SCH 51344
    		Inhibitor 98.70%
    SCH 51344 inhibits Ras induced malignant transformation and prevents anchorage-independent growth of oncogene transformed fibroblasts.
    SCH 51344
  • HY-153821
    PROTAC KRAS G12C degrader-2
    		Degrader 98.45%
    PROTAC KRAS G12C degrader-2 (compound 432) is a modulator of K-Ras protein hydrolysis. PROTAC KRAS G12C degrader-2 is a bifunctional compound, which contain on one end a cereblon inhibitor of apoptosis proteins (IAP) and on the other end a moiety which binds KRAS.
    PROTAC KRAS G12C degrader-2
  • HY-120793
    CMC2.24
    		Inhibitor
    CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC50s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis.
    CMC2.24
  • HY-15031
    l-Naproxen
    		Inhibitor 99.63%
    l-Naproxen ((R)-Naproxen) is an enantiomer of (S)-Naproxen. l-Naproxen can inhibit Cdc42 and Rac1 (EC50=96 μM and 212 μM, respectively), and show anti-tumor activity. l-Naproxen is a nonsteroidal antiinflammatory agent (NSAID).
    l-Naproxen
  • HY-12408A
    6H05 TFA
    		Inhibitor 99.02%
    6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).
    6H05 TFA
  • HY-111446
    EPAC 5376753
    		Inhibitor 98.10%
    EPAC 5376753, a 2-Thiobarbituric acid (HY-77962) derivative, is a selective and allosteric Epac inhibitor. EPAC 5376753 inhibits Epac1 with an IC50 of 4 µM in Swiss 3T3 cells. EPAC 5376753 does not inhibit PKA and adenylyl cyclases.
    EPAC 5376753
  • HY-158409
    Pan-RAS-IN-2
    		Inhibitor 98.00%
    Pan-rasin-2 (compound 6A) is a molecular glues that targets RAS. Pan-rasin-2 has significant inhibitory activity on cell proliferation of RAS mutant cell lines. Pan-rasin-2 can form ternary complexes with cyclophilin A (CYPA) and RAS (ON) proteins and the formation of ternary complexes can block the binding of RAF downstream of RAS, which has anti-tumor effects.
    Pan-RAS-IN-2
  • HY-156668
    Rac1-IN-3
    		Inhibitor 98.28%
    Rac1-IN-3 (Compound 2) is a Rac1 inhibitor with an IC50 of 46.1 μM.
    Rac1-IN-3
  • HY-146243
    TH-Z835
    		Inhibitor 99.58%
    TH-Z835 is a mutant selective KRAS (G12D) inhibitor with an IC50 of 1.6 μM. TH-Z835 inhibits both mantGMPPNP/GPPNP exchange and GPPNP/mantGMPPNP exchange.
    TH-Z835
  • HY-156529
    pan-KRAS-IN-2
    		Inhibitor 98.01%
    pan-KRAS-IN-2 (compound 6) is a pan inhibitor of with IC50s ≤10 nM for KRAS WT and mutants (G12D, G12C, G12V, G12S, G12A, Q61H), and ＞10 μM for KRAS G13D, respectively.
    pan-KRAS-IN-2
  • HY-111432
    CCG-232601
    		Inhibitor 99.00%
    CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma.
    CCG-232601
  • HY-108539A
    (R)-CE3F4
    		Inhibitor ≥99.0%
    (R)-CE3F4 is a potent and selective inhibitor of exchange protein directly activated by cAMP isoform 1 (Epac1), with an IC50 of 4.2 μM, with 10-fold selectivity for Epac1 over Epac2 (IC50, 44 μM). (R)-CE3F4 is more potent than racemic CE3F4 and (S)-CE3F4.
    (R)-CE3F4
  • HY-125873
    KRAS G12C inhibitor 15
    		Inhibitor 98.47%
    KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 22, has an IC50 of 5 nM.
    KRAS G12C inhibitor 15
  • HY-128590
    PHT-7.3
    		Inhibitor 99.29%
    PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (Kd=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity.
    PHT-7.3
  • HY-128771
    K-Ras G12C-IN-4
    		Inhibitor 99.19%
    K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRASG12C.
    K-Ras G12C-IN-4
  • HY-163299
    pan-KRAS-IN-5
    		Inhibitor
    pan-KRAS-IN-5 (compound 15a) is a pan-KRAS translation inhibitor by targeting 5′-UTR RNA G-quadruplexes (rG4s). pan-KRAS-IN-5 induces cell cycle arrest and promptes apoptosis in KRAS-driven cancer cells.
    pan-KRAS-IN-5
  • HY-163594
    Pan-RAS-IN-3
    		Inhibitor 99.66%
    Pan-RAS-IN-3 is a pan-Ras inhibitor, and can be used for study of melanoma and acute myeloid leukaemia.
    Pan-RAS-IN-3
  • HY-163595
    Pan-RAS-IN-4
    		Inhibitor 98.53%
    Pan-RAS-IN-4 (compound 2) is a potent inhibitor of RAS, with the IC50 of ＜ 100 nM for KRAS G12D. Pan-RAS-IN-4 plays an important rile in cancer research.
    Pan-RAS-IN-4
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.